PWMS News Search Results

Back to NewsWire Home
Back to
  Back to PeopleWithMS NewsWire 

March 2008 Off the Wire . . .

 

.

 
/News/Articles/2008/02/28_01raw.shtml

Peptimmune Completes Phase I Study with a Novel Peptide Copolymer for the Treatment of MS


Peptimmune, Inc. a privately held biotechnology company, announced that it has completed its first clinical trial to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of PI-2301, a novel peptide copolymer for the treatment of multiple sclerosis and other autoimmune diseases. PI-2301 is a second generation peptide copolymer from a similar compound class as Copaxone.

E-Mail the NewsWire e-mail the NewsWire ! ! ! StumblinStyle.com - Handpainted and Customized Canes
 with any news items you discover 

copyright 2003 PeopleWithMS.com